Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 8/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14890049 | 0.90 | MAPK1 (0.39) | LIPEABL1UCHL1PDGFRBKDR | |
| SCHEMBL9943204 | 0.82 | LIPE (0.40) | LIPEUCHL1MAPK1LCKDGAT1 | |
| SCHEMBL29653311 | 0.82 | LIPE (0.40) | LIPEUCHL1MAPK1LCKDGAT1 | |
| SCHEMBL18725393 | 0.82 | LIPE (0.40) | LIPEUCHL1MAPK1LCKDGAT1 | |
| SCHEMBL14901987 | 0.81 | SLC2A1 (0.42) | UCHL1KDM4E | |
| SCHEMBL14901970 | 0.76 | MAPK1 (0.41) | ABL1MAPK1LCKKDM4EL3MBTL1 | |
| SCHEMBL14901974 | 0.75 | USP30 (0.37) | LIPE | |
| SCHEMBL14901971 | 0.75 | MAPK1 (0.45) | MAPK1LCKKDM4EL3MBTL1 | |
| SCHEMBL17364616 | 0.74 | SMN1; SMN2 (0.38) | UCHL1KDM4E | |
| SCHEMBL960031 | 0.74 | ALDH1A1 (0.43) | UCHL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346825-B2 | Fused bicyclic oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140378493-A1 | Fused Bicyclic Oxazolidinone CETP Inhibitor | MERCK SHARP & DOHME LLC | 2014-12-25 | — | — | US | disclosed |
| US-8871738-B2 | Fused bicyclic oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME LLC | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378493-A1 | Fused Bicyclic Oxazolidinone CETP Inhibitor | CETP, MTTP, APOB | LIPE 469/4885ABL1 4657/4885UCHL1 4071/4885 |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | CETP, MTTP, APOB | LIPE 469/4885ABL1 4657/4885UCHL1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.